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Abstract Studies suggest that the blockade of 5-HT1A, 5-
HT7, and 5-HT3 receptor may increase the speed of antide-
pressant response. 1-[(2,6-Dimethylphenoxy)ethoxyethyl]-
4-(2-methoxyphenyl)piperazine hydrochloride (HBK-14)
and 1-[(2-chloro-6-methylphenoxy)ethoxyethyl]-4-(2-
methoxyphenyl)piperazine hydrochloride (HBK-15), dual 5-
HT1A and 5-HT7 antagonists, showed significant
antidepressant- and anxiolytic-like properties in our previous
tests in rodents. In this study, we aimed to investigate their
antidepressant potential using mouse model of corticosterone-
induced depression. We chose sucrose preference test, forced
swim test, and elevated plus maze to determine anhedonic-,
antidepressant-, and anxiolytic-like activities. We also evalu-
ated the influence of the active compound on brain-derived
neurotrophic factor (BDNF) and nerve growth factor (NGF)
levels in the hippocampus. Moreover, for both compounds,
we performed biofunctional (5-HT3 receptor) and
pharmacokinetic studies. We found that HBK-14 and HBK-
15 were potent 5-HT3 receptor antagonists. HBK-14 (2.5 mg/
kg) and HBK-15 (1.25 mg/kg) after intravenous (i.v.) and
intraperitoneal (i.p.) administration permeated the blood–
brain barrier with brain/plasma ratio lower than 1. The bio-
availability of studied compounds after i.p. administration was
15% for HBK-14 and 54% for HBK-15. Chronic administra-
tion of HBK-15 (1.25 mg/kg) and fluoxetine (10 mg/kg)
protected corticosterone-treated mice from anhedonic-, de-
pressive-, and anxiety-like behaviors, as well as decreases in
BDNF and NGF levels in the hippocampus. HBK-14 (2.5 mg/
kg) counteracted anxiety-like behaviors in corticosterone-
treated mice. Single administration of HBK-15 (1.25 mg/kg)
and ketamine (1mg/kg) reversed depression-like behavior and
regulated decreased BDNF level in the hippocampus in
corticosterone-treated mice. Our results suggest that simulta-
neous blockade of serotonergic 5-HT1A, 5-HT7, and 5-HT3
receptors might accelerate antidepressant response.
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Introduction
Depression is a prevalent, highly debilitating mental disorder,
in which exact neurobiological mechanisms remain unknown.
Antidepressants, even those recently discovered, are effective
in only half of the patients. Moreover, the clinical response
occurs following weeks to months of treatment. Thus, scien-
tists still search for new, fast-acting antidepressants.
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Single Administration of HBK-15—a Triple 5-HT1A, 5-HT7,
and 5-HT3 Receptor Antagonist—Reverses Depressive-Like
Behaviors in Mouse Model of Depression Induced
by Corticosterone
Although many systems participate in antidepressant-like
effect (reviewed in [1–3]), most antidepressants interact with
serotonergic system. Therefore, compounds that affect seroto-
nin receptors are very interesting targets for researchers.
Except for 5-HT5 receptor (which role in mood disorders is
yet to be determined), most serotonin receptors take part in
antidepressant-like response (for review, see Pytka et al. [1]).
Given the localization and regulatory functions, 5-HT1A re-
ceptors play significant role in mood regulation. The activa-
tion of presynaptic 5-HT1A autoreceptors, expressed in the
raphe nuclei, reduces the firing of serotonin neurons and con-
sequently decreases serotonin release. On the other hand, post-
synaptic heteroreceptors, highly expressed in limbic areas,
such as hippocampus [4], regulate the release of other neuro-
transmitters (e.g., γ-aminobutyric acid or glutamate) [5, 6].
Scientists showed an increase in 5-HT1A autoreceptors in
postmortem brains from depressed suicide victims [7].
Similarly, animal studies proved that 5-HT1A receptor defi-
cient mice were less immobile in the forced swim test and tail
suspension test compared with wild-type controls [8, 9].
Richardson-Jones and colleagues [10] demonstrated that
mice, with lower 5-HT1A autoreceptor levels before treatment,
displayed a robust behavioral response to fluoxetine after both
chronic and subchronic administration. The authors conclud-
ed that increasing serotonergic tone prior treatment with se-
lective serotonin reuptake inhibitors might be more effica-
cious and even faster acting than current antidepressant ther-
apies [10]. Similar conclusions, but concerning 5-HT7 recep-
tors, drewMnie-Filali and colleagues [11], who suggested that
5-HT7 receptor antagonists may represent a new class of an-
tidepressant with faster therapeutic action. The scientists dem-
onstrated that 1-week treatment with SB-269970 (a 5-HT7
receptor antagonist) caused behavioral, electrophysiological,
and neuroanatomical changes that usually occur after long-
term treatment with selective serotonin reuptake inhibitors
[11].
Increasing the speed of antidepressant response might also
be possible by blocking 5-HT3 receptors (for review, see Gupta
et al. [12]). The 5-HT3 receptor differs structurally and func-
tionally from all other serotonin receptors. This ligand-gated
ion channel is cation-selective and mediates neuronal depolar-
ization and excitation. Preclinical experiments suggested that
5-HT3 receptors blockade might contribute to vortioxetine’s
faster onset of action [13]. Moreover, scientists proved that 5-
HT3 receptor antagonism is a significant component of the
drug’s antidepressant effect [13, 14]. Similar results obtained
Eisensamer and colleagues [15], who proved that different
classes of antidepressants act as functional antagonists at the
human 5-HT3A. Moreover, studies on animals indicated that 5-
HT3 receptor antagonists alleviate depressive- and anxiety-like
behaviors in rodents [16–20].
Our previous experiments demonstrated that 1-[(2,6-
d i m e t h y l p h e n o x y ) e t h o x y e t h y l ] - 4 - ( 2 -
methoxyphenyl)piperazine hydrochloride (HBK-14) and
1-[(2-chloro-6-methylphenoxy)ethoxyethyl]-4-(2-
methoxyphenyl)piperazine hydrochloride (HBK-15) were se-
rotonin 5-HT1A (IC50 = 64 nM—HBK-14, IC50 = 19 nM—
HBK-15) and 5-HT7 ( IC50 = 77 nM—HBK-14,
IC50 = 220 nM—HBK-15) receptor antagonists with significant
antidepressant- and anxiolytic-like activities in behavioral tests
in rodents [21]. HBK-15 possessed moderate affinity for dopa-
minergic D2 (Ki = 54) and low for serotonergic 5-HT2A
(Ki = 109) receptors [21]. Although the compound moderately
antagonized D2 (IC50 = 68 nM) and very weakly 5-HT2A recep-
tors (IC50 = 4459 nM), it did not show antipsychotic-like or
cataleptogenic properties (unpublished results). HBK-14 and
HBK-15 presented negligible cholinolytic [22] and antihista-
minic activities [23]. We proved that despite α1-adrenolytic
properties [24], neither HBK-14 nor HBK-15 lowered blood
pressure at antidepressant- and anxiolytic-like doses after chron-
ic treatment [23]. HBK-15 did not exhibit hypotensive activity
even after single administration [24]. Interestingly, unlike most
antidepressants, the compound showed memory-enhancing
properties and ameliorated memory deficits induced by scopol-
amine in mice [23]. Both compounds administered chronically
increased serotonin levels in murine hippocampus [22].
Considering the above data, we hypothesized that HBK-14
and HBK-15 as 5-HT1A and 5-HT7 receptor antagonists,
showing antidepressant- and anxiolytic-like activities in be-
havioral tests in rodents, might have potential to reverse be-
havioral abnormalities in depression model. Therefore, the
aim of our study was to investigate antidepressant- and
anxiolytic-like effects of the compounds using mouse model
of corticosterone-induced depression. We also evaluated the
effect of the active compound on brain-derived neurotrophic
factor (BDNF) and nerve growth factor (NGF) levels in mu-
rine hippocampus, and determined if the compounds interact
with serotonin 5-HT3 receptors. Since pharmacological activ-
ity of every compound depends on its absorption, distribution,
metabolism, and excretion (ADME) properties, we also inves-
tigated the compounds’ pharmacokinetic properties.
Materials and Methods
Animals
Adult male mice (CD-1, 18–21 g) purchased from the Animal
House at the Faculty of Pharmacy, Jagiellonian University
Medical College, Krakow, Poland or male guinea pigs
(Outbred CV, 300–400 g), purchased from Laboratory
Animals Husbandry Maria Staniszewska, Słaboszów,
Poland, were used in the experiments. Animals were kept to
a plastic cage (mice 25.2 cm × 16.7 cm × 14.0 cm, four per
cage; guinea pigs 60 cm × 380 cm × 20 cm, two per cage) at a
room temperature (22 ± 2 °C) on 12 h light/dark cycles (the
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lights on at 7:00 a.m. and off at 19:00 p.m.). Animals had free
access to standard laboratory pellet and tap water. All behav-
ioral procedures were performed between 9 a.m. and 2 p.m.
After the experiments, mice were killed by cervical disloca-
tion, whereas guinea pigs were anesthetized (37 mg/kg sodi-
um pentobarbital) and killed by cervical dislocation.
For pharmacokinetic study, HBK-14 and HBK-15 dis-
solved in saline were administered by an intravenous (i.v.)
and intraperitoneal (i.p.) administration at a dose of 2.5 and
1.25 mg/kg, respectively. Blood samples were collected at
0 min (predose), 5 min, 15 min, 30 min, 60 min, 120 min,
and 240 min after compounds administration. The blood and
brain samples were collected under general anesthesia induced
by i.p. injections of 50mg/kg ketamine plus 8mg/kg xylazine.
Blood samples were collected into heparinized tubes. The
samples were immediately centrifuged at 3500 rpm for
10 min, and plasma was collected. The brain and plasma sam-
ples were immediately frozen at −80 °C for further analysis.
All experimental procedures were carried out in accordance
with EU Directive 2010/63/EU and approved by the I Local
Ethics Committee for Experiments on Animals of the
Jagiellonian University in Krakow, Poland (approval num-
bers: 52/2014, 123/2015, 261/2015, and 104/2016).
Drugs
1 - [ ( 2 , 6 -D ime t h y l p h e n o xy ) e t h o xy e t h y l ] - 4 - ( 2 -
methoxyphenyl)piperazine hydrochloride (HBK-14; Fig. 1a)
and 1-[(2-chloro-6-methylphenoxy)ethoxyethyl]-4-(2-
methoxyphenyl)piperazine hydrochloride (HBK-15; Fig. 1a)
were synthesized in the Department of Bioorganic Chemistry,
Chair of Organic Chemistry, Pharmaceutical Faculty,
Jagiellonian University [25]. HBK-14, HBK-15, fluoxetine
(Sigma, Germany), and ketamine (Sigma, Germany) were dis-
solved in saline, and administered i.p. at a volume of 10 mL/
kg. Corticosterone was dissolved in saline containing 0.1%
dimethyl sulfoxide (DMSO) and 0.1% Tween-80 and admin-
istered subcutaneously (s.c.). Serotonin (Sigma, Germany)
was dissolved in distilled water and used in biofunctional
studies.
The Effect on Guinea Pig Ileum Contractions Induced
by Serotonin
The experiment was performed according to the method de-
scribed by Mogilski and colleagues [26]. A segment (15 cm)
of male guinea pig ileum was excised from the small intestine
and immersed into a Krebs solution (NaCl 120 mM, KCl
5.6 mM, MgCl2 2.2 mM, CaCl2 2.4 mM, NaHCO3 19 mM,
glucose 10 mM). The part of the ileum (5 cm) that was the
closest to the ileo-cecal junction was removed. After 2-cm-
long fragments of the ileumwere cut, each of themwas placed
in 20 mL chamber of tissue organ bath system (Tissue Organ
Bath System—750 TOBS, DMT, Denmark) filled with the
Krebs solution at 37 °C, pH 7.4, with constant oxygenation
(O2/CO2, 19:1). The segments were stretched by means of
closing clips between the metal rod and the force–displace-
ment transducer. The preparations were stabilizing in organ
baths for 60 min under a resting tension of 0.5 g and were
washed every 15 min with fresh Krebs solution. After the
equilibration period, a cumulative concentration–response
curve was constructed for serotonin (3 nM–3 μM). Then, the
tissues were incubated with one of the concentrations of tested
compounds for 15 min, and the next cumulative concentration
curve to the agonist was constructed. Only one concentration
of the potential antagonist was tested in each piece of the tissue.
The experiment was repeated four to eight times.
Experimental Design
Chronic Administration of Studied Compounds
The doses and route of administration of the studied compounds
were based on our previous experiments [21, 22]. Since
antidepressant-like activity of HBK-14 and HBK-15 was due
to the interaction with serotonergic (not adrenergic) system
[21], we chose fluoxetine (selective serotonin reuptake inhibi-
tor) as reference drug. Mice were injected with corticosterone
(s.c., 20 mg/kg) at random times during the light phase for 21
consecutive days (Fig. 1b). The dose and route of administra-
tion of corticosterone was based on studies performed by Zhao
and colleagues [27]. Thirty minutes before, corticosterone in-
jection mice were given (i.p.) saline, HBK-14 (1.25 or 2.5 mg/
kg), HBK-15 (0.625 or 1.25 mg/kg), or fluoxetine (10 mg/kg)
(Fig. 1b). Control mice received (i.p.) saline and 30 min later
saline containing 0.1% dimethyl sulfoxide (DMSO) and 0.1%
Tween-80 (s.c.). The experimental groups consisted of eight
randomly selected animals. After the end of the procedure, an-
imals were tested in the sucrose preference test, forced swim
test, elevated plus maze test, and spontaneous locomotor activ-
ity test. Following behavioral testing, rodents were scarified and
their hippocampi collected for biochemical analysis.
Acute Administration of Studied Compounds
Mice were injected with corticosterone (s.c., 20 mg/kg) at ran-
dom times during the light phase for consecutive 21 days
(Fig. 1c). The dose and route of administration of corticoste-
rone were based on studies performed by Zhao and colleagues
[27]. After the end of the procedure, next day 30min before the
test, corticosterone-treated mice were given (i.p.) saline, HBK-
15 (1.25 mg/kg), fluoxetine (10 mg/kg), or ketamine (1 mg/kg)
(Fig. 1c). Control mice received (i.p.) saline. The experimental
groups consisted of eight randomly selected animals.We chose
the dose of HBK-15 that was active in the chronic experiments
(i.e., 1.25 mg/kg). The dose of ketamine was based on the
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studies performed by Pazini and colleagues [28]. Animals were
tested in the forced swim test and spontaneous locomotor ac-
tivity test. After behavioral testing, mice were scarified and
their hippocampi collected for biochemical analysis.
Spontaneous Locomotor Activity
The locomotor activity was performed as previously described
[29]. Locomotor activity was recorded individually for each
mouse using activity cages made of clear Perspex
(40 cm × 40 cm × 31 cm, Activity Cage 7441, Ugo Basile,
Italy). The cages were supplied with I.R. horizontal beam
emitters connected to a counter for the recording of light-
beam interruptions. Each mouse was placed in a cage for a
30-min habituation period. After that time, the number of
crossings of photobeams was measured for 6 min (chronic
studies) or for 4 min (acute experiments; i.e., the time equal
to the observation period in the forced swim test). The cages
were disinfected with 70% ethanol after each mouse.
Sucrose Preference Test
The sucrose preference test was conducted according to the
slightly modified methods described by Liu and colleagues
Fig. 1 Chemical structures of the studied compounds and schematic
d i a g r a m s o f e x p e r i m e n t a l p r o c e d u r e s . a 1 - [ ( 2 , 6 -
Dimethylphenoxy)ethoxyethyl]-4-(2-methoxyphenyl)piperazine
hydrochloride (HBK-14), 1-[(2-chloro-6-methylphenoxy)ethoxyethyl]-4-
(2-methoxyphenyl)piperazine hydrochloride (HBK-15). b Corticosterone
(20 mg/kg) was injected subcutaneously (s.c.) for 3 weeks at random
times during the light phase. Additionally, 30 min before, corticosterone
administration mice were intraperitoneally (i.p.) injected with HBK-14
(1.25 or 2.5 mg/kg), HBK-15 (0.625 or 1.25 mg/kg), fluoxetine (10 mg/
kg), or 0.9% NaCl (saline). Control groups received saline (i.p.) and
30 min later saline containing 0.1% dimethyl sulfoxide (DMSO) and
0.1% Tween-80 (vehicle, s.c.). c Corticosterone (20 mg/kg) was injected
s.c. to mice for 3 weeks at random times during the light phase. Thirty
minutes before the experiment, mice were i.p. injected with HBK-15
(1.25 mg/kg), ketamine (1 mg/kg), fluoxetine (10 mg/kg), or 0.9%
NaCl (saline). Control group, which was injected for 21 days with saline
containing 0.1% dimethyl sulfoxide (DMSO) and 0.1% Tween-80 (vehi-
cle, s.c.), received saline (i.p.). EPM - elevated plus maze, FST - forced
swim test, LA - locomotor activity, SPT - sucrose preference test, TC -
tissue collection
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[30] and Filho and colleagues [31]. The test was performed
before and after the administration of corticosterone. Briefly,
before the proper test, mice were housed singly and given 72 h
training to acclimate to the test procedures. In the first 24 h,
access ad libitum to two feeding bottles of 1% (w/v) sucrose
solution was given to each mouse. After 24 h, one bottle was
replaced with tap water for the next 24 h. Then, mice were
deprived of water and food for the third 24 h. On the test day,
the weight of each bottle (1% sucrose solution and tap water)
was recorded. Test animals were then given the bottles of 1%
sucrose and water for 24 h. The consumed liquid weight was
measured based on the weight of each bottle of fluids after
sucrose preference test minus the original starting weight. The
percentage of sucrose intake was calculated using the follow-
ing equation:
%Sucrose intake ¼ Sucrose intake
Sucrose intakeþ water intake⋅100%
Forced Swim Test
Forced swim test was performed according to the method
described by Porsolt and colleagues [32] and previously
described [33, 34]. Mice were placed individually for
6 min in glass cylinders (height 25 cm, diameter 10 cm)
containing 10 cm3 of water (23–25 °C). The total time of
immobility was recorded during the final 4 min of the
test. The experiments were recorded and scored using
aLab.io software by a trained observer blind to the
treatments.
Elevated Plus Maze
The elevated plus maze was performed according to the meth-
od previously described [35, 36]. The elevated plus maze for
mice consisted of two opposing open (30 cm × 5 cm), and two
enclosed arms (30 cm × 5 cm × 25 cm) connected by a central
platform forming the shape of a plus sign. The open and
closed arms were connected with a central field (5 cm × 5 cm).
Each mouse was individually placed at the central field of the
apparatus with the head turned toward one of the closed arms.
Animal behavior was observed for 5 min. The device was
disinfected with 70% ethanol after each mouse. The number
of entries to open and closed arms and time spent in the open
and closed arms were measured. The experiments were re-
corded and scored using aLab.io software by a trained observ-
er blind to the treatments.
BDNF and NGF Levels in the Hippocampus
After the behavioral assessments, mice were sacrificed, and
their brains were rapidly removed and chilled in an ice-cold
saline solution. The hippocampi were dissected on a cold
plate, frozen, and stored at −80 °C until assay. On the day of
experiments, tissues were thawed on ice and homogenized
(1:9 w/v) in phosphate-buffered saline (4 °C) and protease
inhibitor cocktail was added. The 10% homogenates were
prepared and homogenized for 30 s with TissueRuptor ho-
mogenizer. The homogenized tissues were centrifuged
(2500×g at 4 °C for 20 min), and the supernatants were col-
lected for further assays.
Protein concentrations of BDNF and NGF in homoge-
nates from hippocampi were determined using the
enzyme-linked immunosorbent assay (ELISA) kits
(BDNF: DZE201020014, SunRed Biotechnology
Company; NGF: MBS825100, MyBioSource) according
to the manufacturer’s instructions. Serial dilutions of the
standards were performed to make the standard curve within
the range of this assay (BDNF 0.1–10 ng/mL; NGF 31.2–
2000 pg/mL). The samples were analyzed in duplicates, and
the mean concentrations were calculated. BDNF and NGF
antibodies are high selectivity and thus did not cross-react
with any other cytokines. The reaction was terminated after
the stop solution was added. The intensity of the color was
read at 450 nm. Absorbance was measured in a multifunc-
tion plate reader (POLARstar Omega, BMG Labtech,
Germany). The concentration of the samples was interpo-
lated from the standard curve using GraphPad Prism
Version 6.00 software.
Pharmacokinetic Studies
Pharmacokinetic parameters were calculated by a non-
compartmental approach from the average concentration
values, using Phoenix WinNonlin software (Certara,
Princeton, NJ 08540, USA). First-order elimination rate con-
stant (λz) was calculated by linear regression of time vs log
concentration. Next, the area under the mean serum and brain
concentration vs time curve extrapolated to infinity (AUC0→
∞) was estimated using the log-linear trapezoidal rule (Eq. 1),
where Cn is the concentration of last sampling of each com-
pound.
AUC0→∞ ¼ ∑
n
i¼1
Ci þ Ciþ1ð Þ=2ð Þ⋅ tiþ1−tið Þ þ Cn=λz ð1Þ
Area under the first moment curve (AUMC0→∞) was esti-
mated by calculation of the total area under the first moment
curve and extrapolated area using the Eq. 2, where tn is the
time of last sampling.
AUMC0→∞ ¼ ∑
n
i¼1
ti⋅Ci þ tiþ1⋅Ciþ1ð Þ=2ð Þ⋅ tiþ1−tið Þ
þ tn⋅Cnð Þ=λz þ Cn=λ2z ð2Þ
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Mean residence time (MRT) was calculated as
MRT ¼ AUMC0→∞
AUC0→∞
ð3Þ
Total clearance (ClT) was calculated as
ClT ¼ DivAUC0→∞ ð4Þ
Volume of distribution at steady state (Vss) was calculated as
Vss ¼ Div⋅AUMC0→∞
AUC0→∞
2 ð5Þ
The bioavailability (F) of HBK-14 and HBK-15 after i.p.
administration was calculated as follows
F ¼ AUCi:p:
AUCi:v:
⋅100% ð6Þ
where Div is an i.v. dose of HBK-14 and HBK-15, AUC is the
area under the zero moment curve, and AUMC is the area
under the first moment curve.
Analytical Procedure
The quantification of studied compounds in plasma and brain
samples was accomplished using UFLC Nexera system
(Shimadzu, Kyoto, Japan) coupled to the triple quadrupole
mass spectrometer QTrap 5500 (Sciex, Framingham, MA,
USA) equipped with Turbo V™ ion source. After preparation,
the samples were injected (5 μL) onto Acquity UPLC BEH
C18 (3.0 × 100 mm, 1.7 μm, Waters, Milford, MA, USA)
analytical column. The mobile phases that consisted of ACN
with 0.1% FA (A) and water with 0.1% FA (B) were delivered
in isocratic elution mode (40% A, 60% B) at the flow rate of
550 μL/min. The total time of analysis was 8 min including
2 min of column equilibration.
Electrospray ionization process was performed in positive
polarization, and the data acquisition was carried out in mul-
tiple reaction monitoring mode (MRM) for all analytes and
their internal standard (HBK-11 [37]). The ion spray source
settings were as follows: spray voltage 4.5 kV, heater temper-
ature 450 °C, curtain gas 25 psi, source gas 1 40 psi, source
gas 2 40 psi. All manually optimized parameters for each
analyte including ion transitions and collision energy (CE)
were listed in Table 1.
Sample Preparation
An amount of 50 μL of sample (plasma or brain homogenate)
was transferred into the clean Eppendorf tube and spiked with
5 μL of internal standard solution (IS, 1 μg/mL) obtaining the
final concentration of 100 ng/mL. After 5 min of mixing
(1500 rpm), proteins were precipitated using 150 μL ACN.
After 10 min of samples shaking (1500 rpm), the incubation
step was performed (10 min, 4 °C). Next, samples were cen-
trifuged (10,000 rpm, 10 min, 4 °C) and the supernatant was
transferred into chromatographic vial for LC/MS/MS
analysis.
The brain homogenate was preparedmaintaining the tissue:
phosphate-buffered saline (PBS) ratio at 1:5. The homogeni-
zation was carried out employing IKA® T10 Basic ULTRA-
TURRAX disperser (IKAWerke GmbH & Co. KG, Staufen,
Germany). After homogenization, all samples were centri-
fuged (3000 rpm, 10 min, 4 °C) and 50 μL of supernatant
was collected for further preparation. All samples were stored
on ice during the preparation process.
Standard Solution Preparation
Each studied compound in amount of 5 mg was accurately
weighted and quantitatively transferred into the 5-mL volu-
metric flask using MeOH. After the salts dissolving flask was
filled to the 5 mL mark with MeOH obtaining 1 mg/mL of
particular analyte. Further dilutions were performed using
MeOH to prepare working standard solutions of analytes at
the following concentrations: 0.025, 0.05, 0.1, 0.25, 0.5, 1.0,
2.5, 5.0, 10, 25, and 50 μg/mL for calibration curve (CC)
samples and 0.025, 0.075, 2.2, and 4.5 μg/mL for quality
control (QC) samples.
Avolume of 45μL ofmatrix (plasma or brain homogenate)
was spiked with 5 μL of IS obtaining the final concentration
of 100 ng/mL and 5 μL of standards working solutions at
needed CC or QC concentration levels. After standard solu-
tion addition, samples were mixed and purified in the same
way as unknown (studied) samples.
Data Analysis
Results are presented as means ± S.E.M. The comparisons
between experimental and control groups were performed by
Table 1 The ion transitions selected for studied compounds
quantification and internal standard registration as well as all manually
optimized parameters including collision energy (CE), declustering
potential (DP), entrance potential (EP), and collision cell exit potential
(CXP)
Analyte MRM (m/z) CE [V] DP [V] EP [V] CXP [V]
HBK-14 385.2→ 205.3 38 140 15 10
HBK-15 405.2→ 190.3 38 100 15 20
IS (HBK-11) 431.2→ 239.2 39 80 15 25
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one-way ANOVA, followed by Newman–Keuls post hoc
(GraphPad Prism version 6.00 software). A value of
p < 0.05 was considered to be significant.
In functional experiments pKB values for non-competitive
antagonists were estimated using double-reciprocal plot meth-
od and the following equation [38]
pKB ¼ −log10
B½ 
slope−1
B½ –molar antagonist concentration
Results
HBK-15 and HBK-14 Decreased Guinea Pig Ileum
Contractions Induced by Serotonin
Serotonin concentration dependently contracted guinea pig
ileum; the pEC50 value (negative logarithm of the agonist
concentration at which the response reached 50% of the max-
imal response) was 5.95 ± 0.07. None of the studied com-
pounds administered alone had effect on ileal contractions
(data not shown). HBK-14 at the concentrations 10, 30, and
100 nM decreased the maximum effect of serotonin by 24, 49,
and 65%, respectively. This suggested a non-competitive an-
tagonism. HBK-15 at the concentrations 30, 100, and 300 nM
decreased the maximal response by 24, 55, and 65%, respec-
tively, which indicated a non-competitive interaction with 5-
HT3 receptors. The pKB values are presented in Table 2.
Chronic Experiments
Chronic Treatment with HBK-15 but Not HBK-14 Prevented
Anhedonic-Like Behavior in Corticosterone-treated Mice
There were no significant differences in sucrose intake be-
tween the studied groups at the beginning of the experiment
[HBK-14 F(4,35) = 0.288, ns; HBK-15 F(4,35) = 0.132,
ns] (data not shown). After 21 days in mice injected with
corticosterone (20 mg/kg) receiving saline, the percentage
intake of sucrose solution was significantly decreased (by
17%—HBK-14, Fig. 2a or 21%—HBK-15, Fig. 3a) com-
pared with control animals. HBK-14 was inactive in this
test [F(4,35) = 4.678; p < 0.01] (Fig. 2a). HBK-15
(1.25 mg/kg but not 0.625 mg/kg) and fluoxetine (10 mg/
kg) administered for 21 days prevented the decrease in su-
crose intake in mice treated with cort icosterone
[F(4,35) = 5.483; p < 0.01] (Fig. 2a).
Chronic Treatment with HBK-15 but Not HBK-14 Prevented
Depressive-Like Behavior in Corticosterone-treated Mice
We observed a significant increase (by 14%—HBK-14,
Fig. 2b or 21%—HBK-15, Fig. 3b) in the immobility in
mice treated with corticosterone (20 mg/kg) receiving sa-
line compared with controls. HBK-14 was inactive in this
test [F(4,35) = 5.030; p < 0.01] (Fig. 2b). HBK-15
(1.25 mg/kg but not 0.625 mg/kg) and fluoxetine (10 mg/
kg) administered for 21 days prevented an increase in im-
mob i l i t y i n m i c e t r e a t e d w i t h co r t i c o s t e r o n e
[F(4,35) = 6.984; p < 0.01] (Fig. 3b).
Chronic Treatment with HBK-15 and HBK-14 Prevented
Anxiety-Like Behavior in Corticosterone-treated Mice
Mice treated with corticosterone (20 mg/kg) receiving sa-
line compared with controls spent significantly less time
(HBK-14: by 48%, Fig. 2c; HBK-15: by 48%, Fig. 3c) in
the open arms and entered the open arms less often (HBK-
14: by 56%, Fig. 2d; HBK-15: by 48%, Fig. 3d). HBK-14
(2.5 mg/kg but not 1.25 mg/kg) and fluoxetine (10 mg/kg)
prevented the decreases in the time spent in the open arms
[F(4,35) = 4.029; p < 0.01], and the number of open arm
entries [F(4,35) = 10.490; p < 0.0001] in mice treated with
corticosterone (Fig. 2c, d). HBK-14 (2.5 mg/kg) signifi-
cantly increased the number of open arms entries compared
with fluoxetine (Fig. 2d). HBK-15 (2.5 mg/kg but not
1.25 mg/kg) and fluoxetine (10 mg/kg) prevented the de-
creases in the time spent in the open arms [F(4,35) = 3.394;
p < 0 . 0 5 ] , a n d t h e numbe r ope n a rm en t r i e s
[F(4,35) = 5.675; p < 0.01] in corticosterone-treated mice
(Fig. 3c, d).
None of the Studied Compounds Administered Chronically
Influenced Locomotor Activity of Corticosterone-Treated
Mice
There were no differences between corticosterone-treated
mice receiving saline and controls (Table 3). Neither HBK-
14 (1.25 and 2.5 mg/kg), HBK-15 (0.625 and 1.25 mg/kg),
nor fluoxetine (10 mg/kg) administered for 21 days influenced
locomotor activity in 6 min session [HBK-14 F(4,35) = 0.384,
Table 2 Functional
affinities of HBK-14 and
HBK-15 for 5-HT3 re-
ceptors expressed in
guinea pig ileum
Compound 5-HT3 receptor
pKB ± S.E.M
HBK-14 7.949 ± 0.10
HBK-15 7.361 ± 0.12
Ondansetron 7.111 ± 0.12a
a [26]
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ns; HBK-15 F(4,35) = 0.371, ns] in corticosterone-treated
mice (Table 3).
Chronic Treatment with HBK-15 Prevented
Corticosterone-Induced Decrease in BDNF Level in Murine
Hippocampus
There was a significant decrease in BDNF level (by 44.0%)
in the hippocampus in mice treated with corticosterone
(20 mg/kg) receiving saline compared with controls
(Fig. 3e). HBK-15 (1.25 but not 0.625 mg/kg) and fluoxe-
tine (10 mg/kg) administered for 21 days protected
corticosterone-treated mice from the decrease in the
BDNF level in the hippocampus [F(4,25) = 5.286;
p < 0.01] (Fig. 3e).
Chronic Treatment with HBK-15 Prevented
Corticosterone-Induced Decrease in NGF Level in Murine
Hippocampus
The level of NGF in murine hippocampus was significantly
lower (35%) in mice treated with corticosterone (20 mg/kg)
receiving saline compared with controls (Fig. 3f). HBK-15
(1.25 but not 0.625 mg/kg) and fluoxetine (10 mg/kg) adminis-
tered for 21 days protected corticosterone-treated mice from the
Fig. 2 Effect of chronic administration HBK-14 and fluoxetine on the
behavior of mice treated with corticosterone. Corticosterone (20 mg/kg)
was injected subcutaneously (s.c.) for 3 weeks at random times during the
light phase. Additionally, 30 min before, corticosterone administration
mice were intraperitoneally (i.p.) injected with HBK-14 (1.25 or
2.5 mg/kg), fluoxetine (10mg/kg), or 0.9%NaCl (saline). Control groups
received saline (i.p.) and 30 min later saline containing 0.1% dimethyl
sulfoxide (DMSO) and 0.1% Tween-80 (vehicle, s.c.). The doses are
indicated in brackets. Statistical analysis: one-way ANOVA (Newman–
Keuls post hoc); *p < 0.05, **p < 0.01 vs control (non-corticosterone-
treated) (saline, gray); #p < 0.05, ###p < 0.001 vs corticosterone-treated
control (saline, red); ^p < 0.05 vs fluoxetine; n = 8 mice per group (color
figure online)
3938 Mol Neurobiol (2018) 55:3931–3945
decrease in the NGF level in the hippocampus [F(4,25) = 9.690;
p < 0.0001] (Fig. 3f).
Acute Experiments
Single Administration of HBK-15 Reversed Depressive-Like
Behavior in Corticosterone-Treated Mice
We observed a significant increase (by 20%; Fig. 3b) in im-
mobility in mice treated with corticosterone (20 mg/kg) re-
ceiving saline compared with controls. HBK-15 (1.25 mg/
kg) and ketamine (1 mg/kg) but not fluoxetine (10 mg/kg)
administered 30 min before the test reversed an increase in
immobility in corticosterone-treated mice [F(4,35) = 9.783;
p < 0.0001] (Fig. 4a).
Acute Treatment with HBK-15 Did Not Influence Locomotor
Activity of Corticosterone-Treated Mice
We did not observe any differences between mice treated with
corticosterone (20 mg/kg) for 21 days, which received saline
and controls (Table 4). Single administration with HBK-15
(1.25 mg/kg), ketamine (1 mg/kg), or fluoxetine (10 mg/kg)
did not influence locomotor activity [F(4,35) = 0.191, ns] of
corticosterone-treated mice (Table 4).
Single Administration of HBK-15 Reversed
Corticosterone-Induced Decrease in BDNF Level in Murine
Hippocampus
There was a significant decrease in BDNF level (by 47.0%) in
the hippocampus in mice treated with corticosterone (20 mg/
kg) for 21 days, which received saline compared with controls
(Fig. 4b). Single administration of HBK-15 (1.25 mg/kg) but
not fluoxetine (10 mg/kg) reversed the decrease in BDNF
level in the hippocampus [F(4,30) = 3.690; p < 0.0001]
(Fig. 4b). Acute treatment with ketamine increased (by 33%)
the level of BDNF in the hippocampus in corticosterone-
treated mice compared with controls (Fig. 4b).
Pharmacokinetic Studies
The mean plasma concentrations vs time for HBK-14 and
HBK-15 after i.v. and i.p. administration are shown in
Fig. 5a, b. The pharmacokinetic parameters calculated for
both compounds by non-compartmental approach are given
in Table 5. The compounds were cleared from mouse body
with varying rate. After the i.v. and i.p. administration of
HBK-14, the terminal half-lives were 323 and 38 min, respec-
tively. For HBK-15, the terminal half-lives were 71 min after
i.v. and 84 min after i.p. administration. The volume of distri-
bution for HBK-14 was greater (11.2 L/kg) than adequate for
HBK-15 (3.5 L/kg) that indicates the ability of these com-
pounds to penetrate to the deep compartments. After i.p. ad-
ministration, both compounds very quickly, within 5 min,
reach the maximum concentration in the blood. HBK-15
reaches higher bioavailability (F = 54%) compared with
HBK-14 (F = 15%). The investigated compounds penetrated
the blood–brain barrier in a similar degree (Fig. 5c, d). After
i.v. administration of HBK-14 and HBK-15, the brain/plasma
ratio was 0.80 and 0.68, respectively, whereas after i.p. admin-
istration of HBK-14 and HBK-15, the brain/plasma ratio was
0.46 and 0.27, respectively. Distribution of HBK-15 to the
Table 3 Effect of chronic
treatment with studied
compounds on locomotor activity
in mice
Treatment Dose of the studied compound (mg/kg) Number of crossings ± S.E.M
Saline + vehicle – 366.0 ± 59.3
Saline + corticosterone – 343.4 ± 27.3
HBK-14 + corticosterone 1.25 406.3 ± 64.2
HBK-14 + corticosterone 2.5 400.8 ± 55.8
Fluoxetine + corticosterone 10 423.3 ± 47.3
Saline + vehicle – 436.9 ± 71.7
Saline + corticosterone – 394.5 ± 67.1
HBK-15 + corticosterone 0.625 466.1 ± 84.8
HBK-15 + corticosterone 1.25 478.9 ± 78.8
Fluoxetine + corticosterone 10 510.3 ± 54.0
Corticosterone (20 mg/kg) was injected subcutaneously (s.c.) for 3 weeks at random times during the light phase.
Additionally, 30 min before, corticosterone administration mice were intraperitoneally (i.p.) injected with HBK-
14 (1.25 or 2.5 mg/kg), HBK-15 (0.625 or 1.25 mg/kg), fluoxetine (10 mg/kg), or 0.9% NaCl (saline). Control
groups received saline (i.p.) and 30 min later saline containing 0.1% dimethyl sulfoxide (DMSO) and 0.1%
Tween-80 (vehicle, s.c.). Statistical analysis: one-way ANOVA (Newman–Keuls post hoc); n = 8 mice per group
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Fig. 3 Effect of chronic administration HBK-15 and fluoxetine on
corticosterone-treated mice behavior (a–c) and BDNF (d) and NGF (e)
levels in the hippocampus. Corticosterone (20 mg/kg) was injected sub-
cutaneously (s.c.) for 3 weeks at random times during the light phase.
Additionally, 30 min before, corticosterone administration mice were
intraperitoneally (i.p.) injected with HBK-15 (0.625 or 1.25 mg/kg), flu-
oxetine (10mg/kg), or 0.9%NaCl (saline). Control groups received saline
(i.p.) and 30min later saline containing 0.1% dimethyl sulfoxide (DMSO)
and 0.1% Tween-80 (vehicle, s.c.). The doses are indicated in brackets.
Statistical analysis: one-way ANOVA (Newman–Keuls post hoc);
*p < 0.05, **p < 0.01 vs control (non-corticosterone-treated ) (saline,
gray); #p < 0.05, ##p < 0.01, ###p < 0.001 vs corticosterone-treated control
(saline, red); n = 8 mice per group (animal studies), n = 6 mice per group
(biochemical studies) (color figure online) BDNF - brain-derived neuro-
trophic factor, NGF - nerve growth factor
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brain was very rapid and the maximal concentration occurred
5 min after i.p. administration (Fig. 5d).
Discussion
We found that a single administration of HBK-15—a triple 5-
HT1A, 5-HT7, and 5-HT3 receptor antagonist—reversed
depression-like behavior and regulated decreased BDNF level
in the hippocampus in mice with corticosterone-induced de-
pressionmodel. Chronic treatment with the studied compound
protected corticosterone-treated mice from anhedonic-, de-
pressive-, and anxiety-like behaviors, as well as decreases in
BDNF and NGF levels in the hippocampus. A structural ana-
logue (HBK-14); however, administered chronically showed
only anxiolytic-like activity. HBK-15 showed desirable
ADME profiles.
Although the data is inconsistent, most reports suggest the
potential role of 5-HT3 antagonists in the treatment of depres-
sion (reviewed in [12]). Moreover, some studies show that 5-
HT3 receptor blockade might result in anxiolytic-like effect
[39, 40]. Bearing that in mind, we tested HBK-14 and HBK-
15 in biofunctional assays to evaluate their effect on 5-HT3
receptors. Our results indicate that both compounds were non-
competitive 5-HT3 receptor antagonists. We think that 5-HT3
receptor antagonism might have contributed to the
antidepressant- and anxiolytic-like effects of the compounds.
Pharmacokinetic properties of compounds influence their
pharmacological action. Therefore, we investigated the phar-
macokinetic profiles of HBK-14 (2.5 mg/kg—active dose)
and HBK-15 (1.25 mg/kg— active dose) after i.v. and i.p.
administration in mice. The concentration of target
compounds in plasma was determined using LC/ESI-MS/
MS system. If 50 μL of plasma was used, concentrations of
both compounds were detectable for at least 4 h after admin-
istration. The pharmacokinetic results showed that the absorp-
tion of both compounds was rapid, with the peak concentra-
tion occurring at 5 min after i.p. administration. HBK-15
showed higher bioavailability (F = 54%) compared with
HBK-14 (F = 15%). HBK-14 compared with HBK-15 dem-
onstrated higher volume of distribution, 11.2 vs 3.5 L/kg.
Both compounds penetrated the blood–brain barrier but the
ratio of the concentrations in the brain-to-plasma was less than
1. Considering the pharmacokinetic study and brain penetra-
tion, we conclude that HBK-15 presents desirable ADME
profile to follow preclinical studies.
Fig. 4 Effect of a single administration of HBK-15, fluoxetine, and
ketamine on the immobility in the forced swim test (a) and BDNF level
in the hippocampus (b) in corticosterone-treated mice. Corticosterone
(20 mg/kg) was injected subcutaneously (s.c.) to mice for 3 weeks at
random times during the light phase. Thirty minutes before the experi-
ment, mice were intraperitoneally (i.p.) injected with HBK-15 (1.25),
ketamine (1 mg/kg), fluoxetine (10 mg/kg), or 0.9% NaCl (saline).
Control group, which was injected for 21 days with saline containing
0.1% dimethyl sulfoxide (DMSO) and 0.1% Tween-80 (vehicle, s.c.),
received saline (i.p.). Statistical analysis: one-way ANOVA (Newman–
Keuls post hoc); *p < 0.05, **p < 0.01 vs control (non-corticosterone-
treated) (saline, gray); ###p < 0.001, ####p < 0.0001 vs corticosterone-
treated control (saline, red); n = 8 mice per group (animal studies),
n = 7 mice per group (biochemical studies) BDNF - brain-derived neuro-
trophic factor
Table 4 Effect of a single administration of studied compounds on
locomotor activity in mice
Treatment Dose of the studied
compound (mg/kg)
Number of
crossings ± S.E.M
Saline + vehicle – 246.5 ± 34.6
Saline + corticosterone – 230.7 ± 15.8
HBK-15 + corticosterone 1.25 245.3 ± 22.5
Ketamine + corticosterone 1 248.7 ± 25.3
Fluoxetine + corticosterone 15 231.9 ± 21.9
Corticosterone (20 mg/kg) was injected subcutaneously (s.c.) to mice for
3 weeks at random times during the light phase. Thirty minutes before,
the experiment mice were intraperitoneally (i.p.) injected with HBK-15
(1.25), ketamine (1mg/kg), fluoxetine (15mg/kg), or 0.9%NaCl (saline).
Control group, which was injected for 21 days with saline containing
0.1% dimethyl sulfoxide (DMSO) and 0.1% Tween-80 (vehicle, s.c.),
received saline (i.p.). Statistical analysis: one-way ANOVA (Newman–
Keuls post hoc); n = 8 mice per group
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Corticosterone-induced model of depression is a widely
used preclinical model. The repeated administration of corti-
costerone induces behavioral (e.g., reduced sucrose consump-
tion [41] or increased immobility in the forced swim test [42])
and neurochemical (e.g., decreased neurogenesis in the hippo-
campus [43, 44]) changes in rodents that mimic some core
symptoms of depression [45]. Antidepressants reverse these
changes [28]. Here, we demonstrated that mice chronically
injected with corticosterone showed anhedonic- (reduced su-
crose consumption), depressive- (increased immobility in the
forced swim test), and anxiety-like (decreased number of en-
tries and time spent in the open arms of the elevated plus
maze) behaviors. HBK-14 (2.5 mg/kg but not 1.25 mg/kg)
administered for 21 days prevented anxiolytic-like behavior,
whereas HBK-15 (1.25 mg/kg but not 0.625 mg/kg) and flu-
oxetine protected corticosterone-treated mice from all above
behaviors. We think that the lower dose of HBK-15 was inac-
tive in this model, because it was insufficient to induce neu-
rochemical changes necessary for antidepressant- and
anxiolytic-like effects. The effect of the higher dose was com-
parable to fluoxetine. Since none of the treatments affected
locomotor activity of mice, the observed results were specific.
Interestingly, HBK-14 prevented corticosterone-treated
mice only from anxiety-like behavior. Although anxiolytic-
like effect (the increase in the number of open arm entries)
was significantly stronger than that of fluoxetine, HBK-14,
unlike HBK-15, failed to protect mice from depressive-like
behaviors. We suggest two possible explanations of this phe-
nomenon. First, it might be due to the slight differences in the
Table 5 Pharmacokinetic parameters for HBK-14 (2.5 mg/kg) and
HBK-15 (1.25 mg/kg) after i.v. and i.p. administrations
Parameters HBK-14 HBK-15
i.v. i.p. i.v. i.p.
C0 [ng/mL] 410 – 602 –
AUC0→∞ [ng min/mL] 103,499 33,617 29,018 15,683
MRT [min] 454.1 48.3 90.2 108.7
t0.5 [min] 322.7 38.2 70.5 83.5
Cmax [ng/mL] – 269.3 – 359
tmax [min] – 5 – 5
Vd [L/kg] 11.2 – 3.5 –
Cl [mL/min/kg] 24.2 – 40.2 –
F [%] 15 54
Twenty-eight adult male mice (CD-1, 20–25 g) were used in the study
C0 the initial concentration, Cmax the maximum plasma concentration,
tmax time to reach the maximum plasma concentration, t0.5 terminal
half-life, MRT mean residence time, AUC0→∞ area under the concentra-
tion–time curve from zero up to infinitive time, Cl systemic clearance, Vd
volume of distribution at steady state, F absolute bioavailability, i.v. in-
travenous, i.p. intraperitoneal
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Fig. 5 Concentration–time profile in plasma (a, b, semilogarithmic plots) and distribution to brain (c, d) for HBK-14 (2.5 mg/kg) and HBK-15
(1.25 mg/kg) after intravenous or intraperitoneal administration to mice
receptor profiles of the compounds—HBK-14, comparedwith
HBK-15, is a weaker 5-HT1A and stronger 5-HT7 receptor
antagonist (the effect on 5-HT3 receptors is comparable)
[21]. According to Wesołowska and colleagues [46], the po-
tent 5-HT7 receptor blockade reduced anxiety-like symptoms
in rodents. Since HBK-14 is stronger 5-HT7 receptor antago-
nist, its anxiolytic-like effect might be more profound. These
findings are consistent with our previous experiments, where
we demonstrated that among the two, HBK-14 possessed
stronger anxiolytic-like properties, whereas HBK-15 antide-
pressant-like activity [21, 22]. The second explanation is sim-
ply the difference in bioavailability—HBK-14 has lower bio-
availability, and this might underlie the lack of antidepressant-
like effect. Perhaps low bioavailability is the reason why we
observed only the stronger, anxiolytic-like, component of the
compound’s activity. Nevertheless, to fully understand this
issue, we need to perform further studies.
Our previous experiments revealed that chronic treatment
with HBK-15 increased serotonin level in the hippocampus
[22]. Serotonin, at least partially, regulates the level of
neurotrophins in the central nervous system [47, 48].
Neurotrophins, such as BDNF or NGF, play important role
in the adaptation of neural networks (including neurogenesis)
that are responsible for different aspects of mood regulation
and antidepressant-like effect (reviewed in [49]). Numerous
studies reported reduced BDNF and NGF levels in patients
with mood disorders [50–53]. Preclinical studies confirm that
low levels of BDNF and NGF result in depressive-like behav-
iors in rodents. Advani and colleagues [54] demonstrated that
a deficiency in BDNF made male mice vulnerable to mild
stress and increased signs of behavioral despair in the forced
swim test (immobility), as well as plasma corticosterone
levels. Other authors proved that a reduction in BDNF expres-
sion in the dentate gyrus reduced neurogenesis and affected
behaviors associated with depression [55]. Moreover, a spe-
cific BDNF knockdown in the ventral subiculum induced
anhedonic-like behavior [55]. Similarly, several animal stud-
ies showed lower NGF levels in the hippocampus and prefron-
tal cortex in chronically stressed rodents [31, 56–58], as well
as antidepressant-like effect of NGF itself [59, 60].
Taking the above data into account, we decided to investi-
gate the influence of HBK-15 on BDNF and NGF levels in
corticosterone-treated mice. Consistent with other studies [28],
we showed that corticosterone administration decreased both
neurotrophins levels in murine hippocampus. Similar to fluox-
etine, HBK-15 (1.25 but not 0.625 mg/kg) administered chron-
ically protected corticosterone-treated mice form these de-
creases. Since most antidepressants upregulate neurotrophins
levels after chronic treatment, this feature of HBK-15 is
beneficial.
Considering the receptor profile and pharmacological activ-
ity of HBK-15, we decided to test its antidepressant potential
after single administration in corticosterone-induced model of
depression. Our results indicate that, similar to ketamine,
HBK-15 (1.25mg/kg) reversed depressive-like behavior, with-
out influencing locomotor activity of animals. Fluoxetine was
inactive after a single administration. As mentioned in the
BIntroduction^ section, the blockade of presynaptic 5-HT1A
autoreceptors, as well as 5-HT7 and 5-HT3 receptors, might
contribute to or even accelerate antidepressant effect. We spec-
ulate that HBK-15 selectively blocked presynaptic 5-HT1A
autoreceptors, which combined with 5-HT7 and 5-HT3 recep-
tor blockade, increased the speed of antidepressant-like re-
sponse. Nevertheless, our theory needs confirmation, as this
effect might be a result of the interaction with other systems.
We also demonstrated that a single administration of HBK-15
(like ketamine but to a lesser extent) upregulated BDNF level
in the hippocampus. Most antidepressants increase BDNF
levels and stimulate neurogenesis, but this effect occurs after
several weeks of administration (maturation of new neurons).
Moreover, we previously reported memory-enhancing proper-
ties of HBK-15 [22]. Since none of the current antidepressants
show rapid clinical effect and significantly improve cognitive
function, our results are very promising.
The limitation of our study was that we did not examine the
precise mechanism underlying the rapid action of HBK-15 in
corticosterone-induced model of depression. Therefore, in fu-
ture studies, we plan to investigate the mechanisms by which
HBK-15 exerted its fast effects. Moreover, since depression is
more prevalent in women than in men, we should also evalu-
ate the activity of HBK-15 in female mice.
Conclusion
We demonstrated that a single administration of HBK-15—a
triple 5-HT1A, 5-HT7, and 5-HT3 receptor antagonist—re-
versed depression-like behavior and regulated decreased
BDNF level in the hippocampus in mouse with
corticosterone-induced model of depression. Chronic treat-
ment with the studied compound protected corticosterone-
treated mice from anhedonic-, depressive-, and anxiety-like
behaviors, as well as deceased BDNF and NGF levels in the
hippocampus. We think that simultaneous 5-HT1A, 5-HT7,
and 5-HT3 receptor blockade might accelerate antidepressant
response, and therefore, HBK-15 requires extended studies to
explore its full pharmacological profile.
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